Fragile histidine triad gene inactivation in lung cancer: The european early lung cancer project

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 5, 2009, Pages 396-401

  Verri, Carla ^a   Roz, Luca ^a   Conte, Davide ^a   Liloglou, Triantafillos ^b   Livio, Anna ^a   Vesin, Aurelien ^c   Fabbri, Alessandra ^a   Andriani, Francesca ^a   Brambilla, Christian ^c   Tavecchio, Luca ^a   Calarco, Giuseppe ^a   Calabrò, Elisa ^a   Mancini, Andrea ^a   Tosi, Diego ^a   Bossi, Paolo ^a   Field, John K ^b   Brambilla, Elisabeth ^c   Sozzi, Gabriella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c INSTITUT ALBERT BONNIOT   (France)

Author keywords

Fhit gene; Lung cancer; Methylation; Prognostic biomarker

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; ACID ANHYDRIDE HYDROLASE; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE INACTIVATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; AGED; BIOSYNTHESIS; CASE CONTROL STUDY; CLINICAL TRIAL; DISEASE COURSE; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROMOTER REGION; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 63349103961     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200807-1153OC     Document Type: Article

References (30)

1. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
2. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002;99:3615-3620.
3. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, Minoletti F, Pilotti S, Ratcliffe C, Veronese ML, et al. Absence of FHIT protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997;57:5207-5212.
4. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD, et al. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res 1997;57:3154-3158.
5. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, et al. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997;57:2256-2267.
6. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996;56:3173-3179.
7. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD, Gazdar AF. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 1995;273:1908.
8. Zochbauer-Muller S, Wistuba II, Minna JD, Gazdar AF. Fragile histidine triad (FHIT) gene abnormalities in lung cancer. Clin Lung Cancer 2000;2:141-145.
9. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032-5037.
10. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001;61:3581-3585.
11. Kim JS, Kim H, Shim YM, Han J, Park J, Kim DH. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 2004;25:2165-2171.
12. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M, Ishizaki K. Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 1998;58:3429-3434.
13. Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, Fabbri A, Andriani F, Tavecchio L, Calabrò E, et al. the EUELC consortium. FHIT gene inactivation in lung cancer patients [abstract]. J Thorac Oncol 2008;S206.
14. Allen D. Histopathology reporting: guidelines for surgical cancer. London: Springer-Verlag, 2006.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
16. Liloglou T, Maloney P, Xinarianos G, Hulbert M, Walshaw MJ, Gosney JR, Turnbull L, Field JK. Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. Cancer Res 2001;61:1624-1628.
17. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA, Tavecchio L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-4678.
18. Skopelitou AS, Gloustianou G, Bai M, Huebner K. FHIT gene expression in human urinary bladder transitional cell carcinomas. In Vivo 2001;15:169-173.
19. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, McCue P, Huebner K. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004;100:1605-1614.
20. Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JT, Kim YT, Mok JE, Munoz N, Bosch FX, Shah K, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997;57:4692-4698.
21. Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R, Huebner K. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005;24:1625-1633.
22. Wali A, Srinivasan R, Shabnam MS, Majumdar S, Joshi K, Behera D. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation. Mol Cancer Res 2006;4:93-99.
23. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006;66:4049-4054.
24. Sozzi G, Miozzo M, Pastorino U, Pilotti S, Donghi R, Giarola M, De Gregorio L, Manenti G, Radice P, Minoletti F. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res 1995;55:135-140.
25. Chang YL, Wu CT, Lin SC, Hsiao CF, Jou YS, Lee YC. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res 2007;13:52-58.
26. Leng S, Stidley CA, Willink R, Bernauer A, Do K, Picchi MA, Sheng X, Frasco MA, Van Den BD, Gilliland FD, et al. Double-strand break damage and associated DNA repair genes predispose smokers to gene methylation. Cancer Res 2008;68:3049-3056.
27. Wistuba II, Mao L, Gazdar AF. Smoking molecular damage in bronchial epithelium. Oncogene 2002;21:7298-7306.
28. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-3344.
29. Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007;99:1257-1269.
30. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111.